Berobenatide vs Bofanglutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
Berobenatide
Developed by Pfizer
NCT06712836 · Phase 2 · completed
The study randomized 239 participants to MET097 or placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical outcome of body-weight change at Week 28. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: January 2027 · NCT07508241 (registry estimate)
Reported efficacy
Percent change from baseline in body weight at Week 28 (Baseline (Week 0) through Week 28 (Day 197)): Percent change in body weight at week 28 (Part A): berobenatide 0.4, 0.6, 0.9 and 1.2 mg weekly -6.41%, -8.36%, -11.29% and -12.45% vs placebo +1.67%; placebo-adjusted -8.09% to -14.13%, all p<0.0001 (CT.gov posted results). (met)
Result source: NCT06712836
Bofanglutide
Developed by Gan & Lee Pharmaceuticals and partners
NCT06737042 · Phase 2 · completed
This randomized Phase 2 study enrolled 326 adults with obesity or overweight, without type 2 diabetes, at 20 US sites. Bofanglutide (24, 36 or 48 mg every 2 weeks) and placebo were given under double-blind conditions, and tirzepatide 15 mg weekly was an open-label comparator. The primary endpoint was percent change in body weight at 36 weeks. Gan & Lee reported on 12 June 2026 that the study met its primary endpoint: the 48 mg group lost 15.18% of body weight and the tirzepatide group 16.93%, in the per-protocol set. The release gives no placebo figure and no p-value, and no registry results are posted.
Next expected readout: June 2027 · NCT07150975 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Berobenatide | Bofanglutide |
|---|---|---|
| Body weight, % change | —Trial running · NCT07311850 | —Not posted · NCT06728124 |
| Weight loss of 5% or more | —Trial running · NCT07311850 | —Not posted · NCT06728124 |
| Weight loss of 10% or more | —Trial running · NCT07311850 | —Not posted · NCT06728124 |
| Waist circumference, change (cm) | —Trial running · NCT07311850 | —Not posted · NCT06728124 |
Body weight, % change
- Berobenatide
- —Trial running · NCT07311850
- Bofanglutide
- —Not posted · NCT06728124
Weight loss of 5% or more
- Berobenatide
- —Trial running · NCT07311850
- Bofanglutide
- —Not posted · NCT06728124
Weight loss of 10% or more
- Berobenatide
- —Trial running · NCT07311850
- Bofanglutide
- —Not posted · NCT06728124
Waist circumference, change (cm)
- Berobenatide
- —Trial running · NCT07311850
- Bofanglutide
- —Not posted · NCT06728124
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Bofanglutide: no structured comparison results are available for Obesity.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
Berobenatide
Developed by Pfizer
NCT06897202 · Phase 2 · completed
The trial randomly assigned 133 participants to MET097 or placebo and was double-blinded, with percent change in body weight as the primary clinical endpoint. However, because no primary efficacy results are available, it is not possible to determine whether the endpoint was met.
Figures from conference coverage of the ADA 2026 presentation; weight change is from baseline, not placebo-adjusted, and no significance testing was reported for the weight endpoint. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: October 2027 · NCT07400653 (registry estimate)
Reported efficacy
Percent change from baseline in body weight at Week 28 (Day 197) (Baseline (Week 0) through Week 28 (Day 197)): Dose-dependent body weight decrease up to 10.2% and HbA1c reduction up to 2.2% at the highest weekly dose
Result source: NCT06897202
Bofanglutide
Developed by Gan & Lee Pharmaceuticals and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2027 · NCT07628985 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Berobenatide | Bofanglutide |
|---|---|---|
| HbA1c, change | —Trial running · NCT07400653 | —Not posted · NCT06777238 |
| Body weight, change (kg) | —Trial running · NCT07400653 | —Not posted · NCT06777238 |
| HbA1c below 7% | —Trial running · NCT07400653 | —Not posted · NCT06777238 |
| Fasting plasma glucose, change | —Trial running · NCT07400653 | —Not posted · NCT06777238 |
| 3-point MACE (% with event) | —Trial running · NCT07400653 | —Not posted · NCT06777238 |
HbA1c, change
- Berobenatide
- —Trial running · NCT07400653
- Bofanglutide
- —Not posted · NCT06777238
Body weight, change (kg)
- Berobenatide
- —Trial running · NCT07400653
- Bofanglutide
- —Not posted · NCT06777238
HbA1c below 7%
- Berobenatide
- —Trial running · NCT07400653
- Bofanglutide
- —Not posted · NCT06777238
Fasting plasma glucose, change
- Berobenatide
- —Trial running · NCT07400653
- Bofanglutide
- —Not posted · NCT06777238
3-point MACE (% with event)
- Berobenatide
- —Trial running · NCT07400653
- Bofanglutide
- —Not posted · NCT06777238
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Bofanglutide: no structured comparison results are available for Type 2 Diabetes.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Berobenatide's landscape · Bofanglutide's landscape